BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 18402522)

  • 1. Emerging therapies for melanoma.
    Katipamula R; Markovic SN
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):553-60. PubMed ID: 18402522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [To outwit melanoma with its own tricks].
    Bischoff A
    MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
    [No Abstract]   [Full Text] [Related]  

  • 3. The systemic treatment of advanced cutaneous melanoma.
    Logan TF
    Facial Plast Surg Clin North Am; 2003 Feb; 11(1):75-85. PubMed ID: 15062290
    [No Abstract]   [Full Text] [Related]  

  • 4. Malignant melanoma.
    Moore GE; Gerner RE
    Surg Gynecol Obstet; 1971 Mar; 132(3):427-36. PubMed ID: 5546295
    [No Abstract]   [Full Text] [Related]  

  • 5. New approaches in metastatic melanoma: biological and molecular targeted therapies.
    Lejeune FJ; Rimoldi D; Speiser D
    Expert Rev Anticancer Ther; 2007 May; 7(5):701-13. PubMed ID: 17492933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy for cutaneous melanoma.
    Treisman J; Garlie N
    Clin Plast Surg; 2010 Jan; 37(1):127-46. PubMed ID: 19914464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and planned multicenter trials for patients with primary or metastatic melanoma.
    Sondak VK; Han D; Deneve J; Kudchadkar R
    J Surg Oncol; 2011 Sep; 104(4):430-7. PubMed ID: 21858839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant application of interferons.
    el Kassas H; Kirkwood JM
    Semin Oncol; 1996 Dec; 23(6):737-43. PubMed ID: 8970596
    [No Abstract]   [Full Text] [Related]  

  • 9. [Guidelines for clinical practice: Standards, Options and Recommendations 2005 for the management of adult patients exhibiting an M0 cutaneous melanoma, full report. National Federation of Cancer Campaign Centers. French Dermatology Society. Update of the 1995 Consensus Conference and the 1998 Standards, Options, and Recommendations].
    Négrier S; Saiag P; Guillot B; Verola O; Avril MF; Bailly C; Cupissol D; Dalac S; Danino A; Dreno B; Grob JJ; Leccia MT; Renaud-Vilmer C; Bosquet L; ;
    Ann Dermatol Venereol; 2005 Dec; 132(12 Pt 2):10S3-10S85. PubMed ID: 16521904
    [No Abstract]   [Full Text] [Related]  

  • 10. [Results of adjuvant therapy with the preparation Poly-a Poly-u in patients with malignant melanoma during a 10-year observation].
    Pawlicki M; Jońca M; Krzemieniecki K; Zuchowska-Vogelgesang B
    Wiad Lek; 1993 Dec; 46(23-24):912-4. PubMed ID: 7900387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of melanoma with an emphasis on immunotherapeutic strategies.
    Jack A; Boyes C; Aydin N; Alam K; Wallack M
    Surg Oncol; 2006 Jul; 15(1):13-24. PubMed ID: 16815006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of malignant melanoma.
    Rosin RD
    Eur J Surg Oncol; 1985 Jun; 11(2):111-5. PubMed ID: 3891412
    [No Abstract]   [Full Text] [Related]  

  • 13. Systemic treatment of metastatic melanoma: new approaches.
    Hamid O; Boasberg PD; Rosenthal K; O'Day SJ
    J Surg Oncol; 2011 Sep; 104(4):425-9. PubMed ID: 21858838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The latest diagnostical methods and therapy in melanoma].
    Wojas-Pelc A; Rajzer L; Jaworek A; Woźniak W
    Przegl Lek; 2006; 63(8):674-80. PubMed ID: 17441381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant immunotherapy. Treatment of high risk patients with malignant melanoma.
    Thomas JH; Maloney BE; Jewell WR
    J Kans Med Soc; 1978 Mar; 79(3):107-10. PubMed ID: 632640
    [No Abstract]   [Full Text] [Related]  

  • 16. [Initial evaluation, diagnosis, staging, treatment, and follow-up of patients with primary cutaneous malignant melanoma. Consensus statement of the Network of Catalan and Balearic Melanoma Centers].
    Mangas C; Paradelo C; Puig S; Gallardo F; Marcoval J; Azon A; Bartralot R; Bel S; Bigatà X; Curcó N; Dalmau J; del Pozo LJ; Ferrándiz C; Formigón M; González A; Just M; Llambrich A; Llistosella E; Malvehy J; Martí RM; Nogués ME; Pedragosa R; Rocamora V; Sàbat M; Salleras M
    Actas Dermosifiliogr; 2010 Mar; 101(2):129-42. PubMed ID: 20223155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment for melanoma].
    Takada M
    Gan To Kagaku Ryoho; 2008 Apr; 35(4):588-90. PubMed ID: 18468001
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant treatment of melanoma using placebo or no therapies as control-arm: is it ethically correct?
    Ascierto PA; Daponte A; Giuseppe P
    Melanoma Res; 1999 Oct; 9(5):528-9. PubMed ID: 10596921
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase III adjuvant studies in operable malignant melanoma (review).
    Lejeune FJ
    Anticancer Res; 1987; 7(4B):701-5. PubMed ID: 3314671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical management of melanoma.
    Brown CK; Kirkwood JM
    Surg Clin North Am; 2003 Apr; 83(2):283-322, viii. PubMed ID: 12744611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.